RadNet, Inc. (NASDAQ:RDNT) EVP David Jeffrey Katz Sells 12,300 Shares

RadNet, Inc. (NASDAQ:RDNT) EVP David Jeffrey Katz sold 12,300 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $81.65, for a total transaction of $1,004,295.00. Following the completion of the transaction, the executive vice president now directly owns 62,909 shares in the company, valued at approximately $5,136,519.85. The trade was a 16.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

RadNet Stock Up 1.3 %

RDNT stock traded up $1.04 on Wednesday, reaching $82.49. 402,553 shares of the company traded hands, compared to its average volume of 551,722. RadNet, Inc. has a one year low of $32.15 and a one year high of $93.65. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. The company has a market cap of $6.11 billion, a P/E ratio of -1,163.41 and a beta of 1.75. The firm has a fifty day simple moving average of $71.61 and a 200-day simple moving average of $64.59.

Analysts Set New Price Targets

Several analysts have issued reports on RDNT shares. Truist Financial upped their price target on shares of RadNet from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Barclays upgraded shares of RadNet from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $57.00 to $79.00 in a research report on Friday, September 6th. Jefferies Financial Group raised their target price on RadNet from $75.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, Sidoti raised shares of RadNet to a “strong-buy” rating in a research report on Friday, October 4th. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.75.

Institutional Trading of RadNet

Institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. lifted its stake in shares of RadNet by 12.0% in the third quarter. Franklin Resources Inc. now owns 387,061 shares of the medical research company’s stock worth $27,334,000 after buying an additional 41,381 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of RadNet in the third quarter worth approximately $211,000. Virtue Capital Management LLC lifted its stake in shares of RadNet by 1.4% in the third quarter. Virtue Capital Management LLC now owns 19,389 shares of the medical research company’s stock worth $1,345,000 after buying an additional 264 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of RadNet by 0.8% in the third quarter. Geode Capital Management LLC now owns 1,555,214 shares of the medical research company’s stock worth $107,936,000 after buying an additional 11,613 shares in the last quarter. Finally, Barclays PLC lifted its stake in shares of RadNet by 373.8% in the third quarter. Barclays PLC now owns 116,978 shares of the medical research company’s stock worth $8,118,000 after buying an additional 92,291 shares in the last quarter. 77.90% of the stock is owned by hedge funds and other institutional investors.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.